Passing of Gustavo Cisneros
Get Alerts GOLD Hot Sheet
Join SI Premium – FREE
TORONTO, Dec. 30, 2023 (GLOBE NEWSWIRE) -- It is with great sadness that the Board of Barrick Gold Corporation (NYSE: GOLD)(TSX: ABX) informs you of the passing of Gustavo Cisneros on December 29, 2023.
Mr. Cisneros was an independent member of the Board from 2003, chairing its Environment, Social and Governance and Nomination Committee and serving as a member of the Compensation Committee. He was also a member of Barrick’s International Advisory Board, which advises the Board on geopolitical and other strategic issues.
Announcing this, Barrick Executive Chairman John Thornton paid tribute to Mr. Cisneros as a business leader of international stature who had built his family-owned Cisneros into a worldwide media, entertainment, telecommunications and consumer products group. He also held board and leadership positions at a wide range of major corporations and institutions.
“Gustavo was an irreplaceable source of wisdom, judgment and insight for decades. He had an uncanny ability to get right to the core of the matter, to see around corners and to give sound, practical, forward leaning advice when one most needed it. His generous and entrepreneurial spirit and his personal and professional integrity will be missed by all of us. Our deepest sympathies, thoughts and prayers are with his wife, Patricia Phelps de Cisneros, his children, Carolina, Guillermo and Adriana, and their families with whom the entire Barrick family shares this heartbreaking loss,” said John Thornton.
EnquiriesInvestor and Media RelationsKathy du Plessis+44 20 7557 7738Email: [email protected]
Website: www.barrick.com
Source: Barrick Gold Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pattern Computer to Participate in Goldman Sachs Private Innovative Company Conference
- Old National Chairman and CEO Jim Ryan Named Chair-Elect of the American Bankers Association
- Beeline Medicines to Present Results from the Phase 2 Trial of Afimetoran in Systemic Lupus Erythematosus as a Late-Breaking Oral Presentation at ACR Convergence 2026
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share